Aim of this study was to determine and further characterize the serum aminopeptidase-M in children with liver diseases. Based on our new assay, we have shown two fractions of the enzyme. Activity of the first fraction is expressed in undiluted serum at pH adjusted from 8.5 (pH of stored serum) to 7.4. Activity of the second fraction (cryptic activity) appears in the serum (pH 7.4) as a result of dilution and/or addition of aniline naphthalene sulfonic acid. In children with Alagille syndrome, extrahepatic biliary duct atresia, Byler’s disease, and acute hepatitis due to hepatitis B virus infection, activities of both fractions are highly elevated as compared to healthy children or those with chronic viral hepatitis. Moreover, serum aminopeptidase-M seems to reflect other aspects of the pathological process than those reflected by the alanine aminotransferase and γ-glutamyltranspeptidase. Due to increased activity and broad substrate specificity, the enzyme seems to be also a cofactor of cholestasis and hepatitis.

Membrane-bound aminopeptidase-M (EC 3.4.11.2) functions as an ectopeptidase at the cell surface in many tissues and there is also a soluble form of this enzyme in serum and other body fluids (1–3). Serum aminopeptidase-M activity is markedly increased in patients with cholestasis and was shown to be a useful marker of hepatobiliary disease (4–7). The enzyme is thought to originate from the liver (2). However, its multiple molecular forms present in serum may arise from other organs and tissues (6, 8).

In hematology, aminopeptidase-M (cluster of differentiation 13) is a well-recognized marker of myeloid cell leukemia (9–11). Interestingly, it has been found that aminopeptidase-M on alimentary or respiratory tract epithelial cells is a receptor for human coronavirus 229E (12). In a large population of apparently healthy humans, the enzyme activity seems to exhibit some variations that are dependent on age, sex, alcohol consumption, smoking, and drug intake (13).

Among the substrates of aminopeptidase-M, including those involved in growth and differentiation regulation, phagocytosis, and bactericidal and tumoricidal activity (3, 4, 9, 14–16), both methionine (met) and leucine (leu) enkephalins are rapidly degraded after their administration to humans or animals (17–28). In circulation, the endogenous enkephalins seem to be protected from degradation through binding to carrier proteins (19). However, a free fraction of the enkephalins would be susceptible to the enzyme.
Enkephalins appear to be implicated in cholestatic liver disease and may be an important pathogenic factor in such complications as pruritus or encephalopathy. Indeed, plasma enkephalin concentrations are highly elevated in adult patients with cholestasis of differing aetiologies (7, 29–32), and in rats with an experimental model of acute cholestasis (33, 34). Accumulating in blood, enkephalins may cross the blood–brain barrier and evoke, via their increased availability in the central nervous system, a syndrome of chronic opiate-receptor stimulation (35, 36). Preliminary experiments have shown that naloxy or nalmefene, opiate-receptor antagonists, ameliorated or reversed pruritus in patients with chronic cholestatic liver disease and, in some patients, precipitated a syndrome that resembles the withdrawal reaction of opiate addiction (37, 38).

Recently, we have shown that in children with cholestasis of differing etiologies increased serum met-enkephalin occurs concomitantly with highly elevated serum aminopeptidase-M activity and that both parameters were apparently not affected by a short-term treatment with ursodeoxycholic acid (39, 40). Alternations in the aminopeptidase-M activity as well as their relevance to the situation in cholestasis and viral hepatitis are not fully understood yet, and further systematic studies seem to be worthwhile. Therefore, in this study we attempted to further characterize and compare the serum aminopeptidase-M activity in healthy children, children with cholestatic liver disease, and children with chronic or acute hepatitis due to hepatitis B virus (HBV) infection.

### MATERIALS AND METHODS

**Patients.** The protocol of this study was approved by the hospital ethics committee. The following groups of patients were included in the study: group 1, eight children, 8–14 years old (mean 10 years), with Alagille syndrome (arterio-hepatic dysplasia), alanine aminotransferase (ALAT): 158 ± 69 units/liter, γ-glutamyltranspeptidase (γGTP): 248 ± 57 units/liter; group 2, eight children, 3 months–2.5 years old (mean 1.5 years), with extrahepatic biliary duct atresia, ALAT: 198 ± 49 units/liter, γGTP: 301 ± 109 units/liter; group 3, seven children, 6–12 years old (mean 8 years), with Byler’s disease (progressive intrahepatic familial cholestasis), ALAT: 91 ± 18 units/liter, γGTP: 15.8 ± 6.0 units/liter; group 4, seven children, 5–14 years old (mean 9 years), with chronic active hepatitis due to hepatitis B virus (HBV) infection, ALAT: 69 ± 15 units/liter, γGTP: 7.5 ± 8.9 units/liter; group 5, six children, 11–17 years old (mean 14 years), with acute hepatitis due to HBV infection, ALAT: 1145 ± 450 units/liter, γGTP: 438 ± 112 units/liter in four patients and 63 and 74 units/liter in two; and group 6, nine apparently healthy children, 6–14 years old (mean 10 years), ALAT: 21 ± 8.4 units/liter, γGTP: 13.8 ± 7.2 units/liter.

**Blood Sampling.** Venous blood was sampled without anticoagulants for the diagnostic examinations; it was possible to use part of each sample in this study. Blood samples were centrifuged at 3000g for 15 min at 4°C, and the sera filtered through a 0.2-μm filter (Sartorius-Membranfilter, Gottingen, Germany) to exclude all residual cell debris, and stored at –30°C. Serum pH was measured using a pH microelectrode (Sigma Chemical Co., St Louis, Missouri).

**Assay of Aminopeptidase-M Activity.** Equal aliquots (500 μl) of the sera were pooled in groups 1–6, respectively, and used for characterization of the aminopeptidase-M. The enzyme activity was also determined in the individual serum samples from patients from groups 1–6. Dilution of the serum was performed using 25 mmol/liter bisTris–Tris–acetic acid buffer with or without 0.15 mol/liter NaCl, at pH range 4.5–9.0. To maintain the serum pH at a desired level, the endogenous HCO₃⁻ was hydrolyzed with a negligible volume of 1 mol/liter HCl (final concentration 25–30 mmol/liter). Resulting CO₂ was removed under low pressure, and pH was adjusted with a small volume of 1 mol/liter NaOH, HCl, or bisTris–Tris–acetic acid under the control of a pH microelectrode.

The incubation mixture consisted of 100 μl of undiluted or diluted serum and 5 μl of [¹²⁵I] or [³H]leu-enkephalin as substrate (100 pmol/liter), from Incstar, Stillwater, Minnesota and DuPont NEN, Boston, Massachusetts, respectively, with specific activities ~ 500 Ci/mmol and ~ 80 Ci/mmol, respectively.

Incubation was performed at 37°C for 0 min (control) to 15 min, and terminated by acidification with 100 mmol/l acetic acid. Degradation of the substrates was quantified by the aluminum silicate binding assay as recently described (41) with slight modifications. A homogenous suspension (50 mg/ml) of aluminum silicate powder (Lloyd reagent, Pfaltz and Bauer, Waterbury, Connecticut) was prepared in 1% acetic acid. Aliquots of 2 ml were added to the tubes at the end of each incubation period. After vortexing for 1 min, the tubes were centrifuged at 3000g for 10 min. For [¹²⁵I]leu-enkephalin, the supernatants were discarded by aspiration, and the silicate pellets counted for the γ-radioactivity. For the [³H]leu-enkephalin, 1.5-ml aliquots of the supernatants were mixed with 5 ml aliquots of the scintillation cocktail and counted for the β-radioactivity. Intra- and interassay coefficients of variation were 4.9% and 10.5% for iodinated and 8.9% and 14.5% for tritiated enkephalins, respectively.

The enzyme activity was expressed as picograms of degraded substrate per minute per milliliter whole serum.

Intact [¹²⁵I]- or [³H]leu-enkephalin was almost completely adsorbed by the aluminum silicate (93 ± 3%, mean ± SEM, N > 30). Reverse-phase high-performance liquid chromatography showed that silicate pellet-bound radioactivity represented the intact labeled peptide, whereas 85–90% of the radioactivity appearing in the supernatants was due to [³H]leu-enkephalin. Unidentified, two to three amino acid fragments constituted about 10–15% of the radioactivity and did not react with the specific leu-enkephalin antibody (data not shown).

**Effect of Inhibitors and Other Substances on Aminopeptidase-M.** Degradation of the labeled leu-enkephalin by
serum aminopeptidase-M was quantified by determining the percentage of intact label in the presence of increasing concentrations of specified substances. The extent of the label degradation in the control probes, no substance added (35–40% degradation after a specified incubation period) was taken as 100% relative activity. Before the assay, the inhibitors to be tested were preincubated with the serum at \( \sim 20^\circ C \) for 15 min. The inhibitory constants (\( K_i \)) and Michaelis constant (\( K_M \)) towards unlabeled leu-enkephalin were determined as previously described (39).

The following substances used in the present study were purchased from Sigma: 1,10-phenanthroline, bestatin, puromycin, leu-enkephalin, met-enkephalin, bovine serum albumin, 8-anilino naphthalene sulfonic (ANS) acid, taurocholic acid, ursodeoxycholic acid, and cholic acid. Other chemicals were of analytical grade.

**Statistical Analysis.** Values are expressed as means ± SEM unless otherwise specified. The Mann-Whitney U test was used to determine the significance of differences between means; \( P < 0.05 \) was considered significant.

**RESULTS**

During storage, serum pH rises to 8.5. The effect of pH on aminopeptidase-M activity in undiluted serum pools from groups 1–6 is shown in Figure 1. The pH curves were symmetric and dynamic with an optimum at about 6.5–7.3 for both iodinated and tritiated leu-enkephalin. The same data were obtained in the experiments with diluted sera.

The increase in serum aminopeptidase-M activity as a result of dilution with 25 mmol/liter buffer, pH 7.4, is shown in Figure 2a,b. As shown in Figure 2a, the enzyme activity increased from 45 ± 5 (undiluted serum, pH 7.4) up to maximal values of 880 ± 90 pg/min/ml (80-fold diluted serum; values are means ± SEM). There were no statistically significant differences in the aminopeptidase-M activity between healthy children and those with chronic active hepatitis due to HBV infection (\( P > 0.05 \)). As shown in Figure 2b, the enzyme activity in the undiluted sera, pH 7.4, from children with Alagille syndrome, extrahepatic biliary duct atresia, Byler’s disease, and acute hepatitis due to HBV infection was: 411 ± 55, 480 ± 39, 198 ± 25, and 300 ± 69 pg/min/ml, respectively. In the samples diluted 50- to 80-fold, the activity reached maximal values of 6100 ± 800, 6900 ± 950, 2150 ± 280, and 3880 ± 410 pg/min/ml, respectively. Negligible dilution, up to 1.5-fold, was without effect (Figure 2a,b). The same data were obtained in the exper-
iments where buffered saline, pH 7.4, served as a serum diluent (data not shown).

The effect of the increasing concentrations of ANS acid on aminopeptidase-M activity is shown in Figure 3. In the undiluted and 5- and 30-fold diluted sera, the enzyme activity increased about twice in the presence of 5, 1 and 0.1 mmol/liter ANS acid, respectively. For any dilution, an optimal concentration (C) of the ANS acid may be estimated from the following empirical formula: 5/A = C (in millimoles per liter), where A is the -fold dilution of the serum. Higher ANS acid concentrations were inhibitory, but the enzyme activity did not decrease below its basal level (no ANS acid added). Inhibition and substrate specificity data of serum aminopeptidase-M in the serum pools in groups 1–6 are shown in Table 1. In both undiluted and diluted sera, puromycin, bestatin, and amastatin inhibited the enzyme with \( K_i \) values of about 70 \( \mu \)mol/liter, 1.8 \( \mu \)mol/liter, and 70 nmol/liter, respectively. In the presence of ANS acid, the enzyme sensitivity to the inhibitors was changed to a certain degree; however, potency and selectivity ranges of the inhibitors remained unchanged. The \( K_M \) value, determined with leu-enkephalin as substrate, was 359 ± 62 nmol/liter in both undiluted and diluted sera from groups 1–6 (Table 1).

Aminopeptidase-M activity in the individual sera from groups 1–6 was evaluated under different assay conditions, and the results are shown in Table 2. In the undiluted samples with pH 8.5, the enzyme activity was statistically significantly underestimated (\( P < 0.005 \)) as compared to the same samples with pH adjusted to the physiological level. Maximal enzyme activity where buffered saline, pH 7.4, served as a serum diluent (data not shown).

![Fig 3. Effect of 8-anilino naphtalene sulfonic acid on the serum aminopeptidase-M activity. The pH of pooled sera from groups 1–6 was adjusted to 7.4, dilutions were performed with 25 mmol/liter bistris-Tris–acetic acid, pH 7.4, and the enzyme activity was determined in duplicate for each serum pool and each dilution using 100 pmol/liter [125I]leu-enkephalin as described in Materials and Methods. Data are means ± SEM.](image)

### Table 1. Inhibition and Substrate Specificity Characteristics of Serum Aminopeptidase-M in Healthy Children and Children with Cholestasis and Acute or Chronic Hepatitis Due to HBV Infection*

| Serum pools (pH 7.4) | \( K_i \) (\( \mu \)mol/liter) | \( K_m \) (\( \mu \)mol/liter) |
|----------------------|-----------------|-----------------|
| Puromycin            | Bestatin        | Amastatin       |
| Undiluted            | 72.0 ± 8.3      | 1.80 ± 0.20     | 0.070 ± 0.011 |
| Diluted 50-fold      | 69.0 ± 4.9      | 2.10 ± 0.14     | 0.066 ± 0.012 |
| Diluted 50-fold + 0.1 mmol/L ANS | 78.0 ± 9.5 | 0.59 ± 0.09 | 0.150 ± 0.021 |

* For each serum pool (groups 1–6), determinations were performed in triplicates. Data are presented as means ± SEM.

### Table 2. Serum Aminopeptidase-M Activity in Healthy Children and Children with Liver Diseases

| Serum sample          | Healthy subjects (N = 9) | Chronic hepatitis (N = 7) | Acute hepatitis (N = 6)* | Alagille syndrome (N = 8)* | Extrahepatic atresia (N = 8)* | Byler's disease (N = 7)* |
|-----------------------|--------------------------|---------------------------|--------------------------|---------------------------|-----------------------------|--------------------------|
| Undiluted, pH 8.5     | 9 ± 5                    | 9 ± 8                     | 69 ± 11                  | 79 ± 15                   | 142 ± 18                    | 44 ± 14                  |
| Undiluted, pH 7.4     | 59 ± 12                  | 89 ± 20                   | 305 ± 175               | 356 ± 110                | 427 ± 140                   | 240 ± 90                 |
| 80-fold diluted, pH 7.4 | 890 ± 205                | 805 ± 283                | 3275 ± 1410             | 6285 ± 1456             | 6580 ± 1928                | 1975 ± 190              |
| 80-fold diluted, pH 7.4 + 0.06 mmol/L ANS | 1621 ± 392 | 1503 ± 409 | 6058 ± 1899 | 14281 ± 3500 | 15127 ± 4025 | 3830 ± 490 |

* P < 0.001 versus healthy children and those with chronic active hepatitis. Values are expressed as means ± SEM.

† 8-anilino naphthalene sulfonic acid.
activity was observed in the samples that were diluted 80-fold. The serum aminopeptidase-M activity was statistically significantly higher in children with cholestasis and acute hepatitis as compared to healthy children or those with chronic active hepatitis ($P < 0.005$).

**DISCUSSION**

We attempted to determine and characterize the expression and properties of serum aminopeptidase-M activity in children with liver diseases and in healthy children. We have shown the presence of two fractions of the enzyme. Activity of the first fraction (basic activity) is expressed in the undiluted or negligibly diluted serum at pH 7.4. Activity of the second fraction (cryptic activity) appears in the serum as a result of dilution and/or addition of ANS acid. In children with cholestasis and in children with acute hepatitis due to HBV infection, both fractions of the enzyme are highly elevated as compared to healthy children or those with chronic active hepatitis due to HBV infection.

Since enkephalins are among the well-characterized, natural aminopeptidase-M substrates (2, 3, 17, 19–28), in our assay we used radiolabeled leu-enkephalin at a concentration close to the peptide level in circulation. [$^3$H]Leu-enkephalin is biologically indistinguishable from the native peptide whereas substitution of the iodine seemingly influenced the substrate–enzyme interaction, resulting in a slightly decreased rate of hydrolysis (Figure 1). The enzyme pH optimum was narrow, about 6.5–7.3, and the activity dramatically decreased outside that range. After one freeze–thaw cycle, the pH of serum increases to 8.5 due to near complete CO$_2$ evaporation. To avoid a serious underestimation of the enzyme activity (20–24, 26, 39, 40), serum pH must be carefully adjusted to 7.4 or, alternatively, to the enzyme pH optimum. Maintaining the serum pH may be achieved by dilution of serum with an appropriate buffer. However, as we have shown, a dilution is another factor affecting the serum aminopeptidase-M activity. Whether pH plays a role in in vivo regulation of the enzyme activity remains to be determined. Aminopeptidase-M activity dynamically increased as a result of dilution of the serum with simple buffer or buffered saline. The plateau of the activity was found in the samples diluted 50- to 80-fold, whereas a negligible dilution, up to 1.5-fold, was without effect. In healthy children and children with chronic active hepatitis due to HBV infection, enzyme activity increased from 70 (undiluted serum) to 900 pg/min/ml (80-fold diluted serum). In children with Byler’s disease, the respective values were 240 and 2000 pg/min/ml. The highest increases were found in children with Alagille syndrome (from 360 to 6300 pg/min/ml), extrahepatic biliary duct atresia (from 430 to 6600 pg/min/ml), and those with acute hepatitis due to HBV infection (from 300 to 4000 pg/min/ml). In many reports (6, 7, 11, 13, 19, 23, 27, 33), including ours (39, 40), serum dilution was not taken into account as a factor that may affect aminopeptidase-M activity. An increase of enzyme activity as a result of dilution suggests that a large portion of the enzyme molecules is not hydrolytically active and is present in the serum as a cryptic fraction. This may be due to presence of the enzyme natural inhibitor(s) that dissociate as a result of dilution. If this assumption is true, then an increase of the serum aminopeptidase-M in cholestasis and acute hepatitis is not due to a deficiency of such an inhibitor since both fractions of the enzyme are highly elevated. Activation of the enzyme may occur in vivo. Recently, Martinez and coworkers (20, 26) have shown that serum aminopeptidase-M activity in rats is capable of changing rapidly in response to environmental experience. However, the mechanism of enzyme activation as a result of serum dilution remains to be determined. Addition of ANS acid, capable of disrupting weak bonds, increased serum aminopeptidase-M activity in a dose-dependent manner (Figure 3). However, the mechanisms of increasing enzyme activity by ANS acid and by dilution seem to be different, and both factors appear to act independently on the enzyme structure, on regulatory factors, or both. Our inhibition and specificity data have shown substantially the same characteristics of the enzyme both in the undiluted and diluted sera determined with or without the presence of ANS acid. Our data suggest that a reliable aminopeptidase-M assay may be performed using a picomolar concentration of the enkephalin labeled with iodine or tritium, added at a negligible volume to an aliquot of the undiluted serum with pH adjusted to the physiological level. Maximal enzyme activity may be determined using 50- to 80-fold-diluted serum. Hemolysis must be avoided since erythrocytes contain an abundance of enkephalin-degrading activity (40). Use of EDTA plasma, phosphate, citrate, or barbital buffers markedly decreases the enzyme activity. For the monitoring of aminopeptidase-M activity, a variety of substrates (6–9, 11, 13, 18–26, 28, 33, 42) and techniques may be applied (7–11, 20–22, 24, 27, 42); however, we have shown here that a sensitive, fast, and inexpensive
aluminumsilicate binding assay is an excellent method for detection of degradation of $^3$H- or $^{125}$I-labeled enkephalins.

Cholestasis is associated with an accumulation of enkephalins and other opiate peptides in blood that may contribute to pathogenesis of pruritus or encephalopathy (7, 29–39). Whether the opioid system is altered in acute viral hepatitis remains to be determined. Although the origin of enkephalins in cholestasis is unknown (35), it seems that an impairment of the hepatic degradation of these peptides does not occur (40). Therefore, an increase of serum aminopeptidase-M in cholestasis may be speculated to be a homeostatic attempt to prevent unlimited accumulation of opiate peptides in circulation. However, due to increased activity, the enzyme seems to cause substantial changes in the turnover of other, biologically active peptides in the blood (43). Therefore, we suggest that the enzyme is not only a marker but also a cofactor of the disease. The source of serum aminopeptidase-M was not proven, but the enzyme is thought to originate from the liver (2), where it is a hepatocyte-membrane-bound metallopeptidase virtually absent in the hepatocyte cytosol. The enzyme may reflect other pathways or aspects of the pathological process than those reflected by serum ALAT or γGTP. Indeed, our patients with Byler’s disease (see Materials and Methods) had a normal level of the serum γGTP, moderately increased ALAT, and high levels of aminopeptidase-M. In contrast, children with active chronic hepatitis had elevated levels of γGTP and ALAT but normal aminopeptidase-M activity. Among our six patients with acute hepatitis due to HBV infection (ALAT > 600 units/liter), two patients had moderately elevated γGTP and highly increased aminopeptidase-M activity whereas four other patients exhibited high increase of both parameters.

Aminopeptidase-M in the serum exhibits a high amplitude of changes both in cholestasis and acute viral hepatitis. However, its physiological and pathophysiological role, as well as its relevance to the situation in cholestatic liver diseases and viral hepatitis will require further studies. Our data seem to provide new, important insights for further studies on a role of this enzyme.

ACKNOWLEDGMENTS

We thank Dr. H. Falk, Falk Foundation e.V., Freiburg, Germany, for a travel grant funded to R.M.J., as a result of which we were able to present part of the present data at the X International Congress of Liver Diseases, October 19–21, 1995, Basel, Switzerland.

REFERENCES

1. Hersh LB, Aboukhair N, Watson S: Immunocytochemical localisation of aminopeptidase-M in rat brain and periphery: Relationship of the enzyme localisation and enkephalin metabolism. Peptides 8:523–532, 1987
2. Roques BP, Beaumont A, Dauge V, Fournie-Zaluski M-C: Peptidase inactivation of enkephalins: Design of inhibitors and biochemical, pharmacological and clinical applications. In Handbook of Experimental Pharmacology. A Hertz (ed). Berlin, Springer-Verlag, 1993, pp 547–584
3. Kenny AJ, Hooper NM: Peptidases involved in the metabolism of bioactive peptides. In Degradation of Bioactive Substances: Physiology and Pathophysiology. JH Henrickson (ed). Boca Raton, Florida, CRC Press, 1991, pp 47–79
4. Peters JE, Nilius R, Otto L: Elektrophoretische Varianten der Alalin–Aminopeptidase in Serum bei hepatobiliarären Erkrankungen. Clin Chim Acta 45:177–187, 1973
5. Tokioka - Terao M, Hiwada K, Kokubu T: A radioimmunoassay for the measurement of aminopeptidase (microsomal) in human serum. Enzyme 33:181–187, 1985
6. Sanderink G-J, Artur Y, Paille F, Siest G: Clinical significance of a new isof orm of serum alanine aminopeptidase: relationship with liver disease and alcohol consumption. Clin Chim Acta 179:23–32, 1989
7. Favaloro EJ, Browning T, Nandurkar H: The hepatobiliary disease marker serum alanine aminopeptidase predominantly comprises an isof orm of the haematological myeloid differentiation antigen and leukaemia marker CD-13/gp150. Clin Chim Acta 220:81–90, 1993
8. Sidorowicz W, Hsia W, Maslej-Zownir O, Behal FJ: Multiple molecular forms of human alanine aminopeptidase: Immunological properties. Clin Chim Acta 107:245–256, 1980
9. Ashmun RA, Look AT: Metalloprotease activity of CD13/ aminopeptidase-N on the surface of human myeloid cells. Blood 75:462–469, 1990
10. Look AT, Ashmun RA, Shapiro LH, Peiper SC: Human myeloid plasma membrane glycoprotein CD-13 (gp150) is identical to aminopeptidase-N. J Clin Invest 83:1299–1307, 1989
11. Favaloro EJ, Browning T, Facey D: CD13 (GP 150; aminopeptidase-N): predominant functional activity in blood cells is localised to plasma and is not cell-surface associated. Exp Hematol 21:1695–1701, 1993
12. Yeager CL, Ashmun RA, Williams RK, Cardellachio CB, Shapiro LH, Look AT, Holmes KV: Human aminopeptidase-N is a receptor for human coronavirus 229E. Nature 357:420–422, 1992
13. Sanderink G-J, Artur Y, Schiele F, Gueguen R, Siest G: Alaline aminopeptidase in serum: Biological variations and reference limits. Clin Chim Acta 34 (7):1422–1426, 1988
14. Gibson AM, Biggins JA, Lauffart B, Mantele D, McDermott JR: Human brain leucyl aminopeptidase: Isolation, characterisation and specificity against some neuropeptides. Neuropeptides 19:163–168, 1991
15. Mizutani S, Goto K, Nomura S, Ito K, Kikawa F, Kurauchi D, Goldstein D, Tomoda Y: Possible action of human placental aminopeptidase-N in fetoplacental unit. Res Commun Chem Pathol Pharmacol 82:65–80, 1993
16. Kenny AJ, O’Hare MJ, Gusterson BA: Cell-surface peptidases
as modulators of growth and differentiation. Lancet 30:785–787, 1989
17. Boarder MR, McArdle W: Breakdown of small enkephalin deriviates and adrenal peptide E by human plasma. Biochem Pharmacol 35:1043–1047, 1986
18. Lulu K, Lampelo S, Vanha-Perttula T: Characterisation of three aminopeptidases purified from maternal serum. Biochim Biophys Acta 873:190–197, 1986
19. Venturrelli F, Roscetti G, Roda LG: Mechanism protecting plasma peptides from enzyme hydrolysis: A comparative study. Comp Biochem Physiol 87B:485–488, 1987
20. Martinez JL, Weinberger SB: Enkephalin hydrolysis in plasma is highly correlated with escape performance in the rat. Behav Neurosci 102:404–408, 1988
21. Weinberger SB, Martinez JL: Characterisation of hydrolysis of [Leu] enkephalin and D-alanine-1-leu enkephalin in rat plasma. J Pharmacol Exp Ther 102:404–408, 1988
22. Shibanoki S, Weinberger SB, Ishikawa K, Martinez JL: Sensitive method for measuring hydrolysis of enkephalins in plasma, using high-performance liquid chromatography with electrochemical detection. J Chromatogr 532:249–259, 1990
23. Berder IF, Hirsh EM, Tuchman AJ, Wards PE: N-terminal degradation of low molecular weight opioid peptides in human cerebrospinal fluid. Biochem Pharmacol 40:465–472, 1990
24. Shibanoki S, Weinberger SB, Ishikawa K, Martinez JL: Further characterisation of the in vitro hydrolysis of [Leu]- and [Met]enkephalin in rat plasma: HPLC-ECD measurements of substrate and metabolite concentrations. Regul Pept 32:267–278, 1992
25. Jonak PH, Schulteis G, Martinez JL Jr: Uptake and metabolism of [3H]-Leu-enkephalin following either its intraperitoneal or subcutaneous administration to mice. Peptides 13:551–555, 1992
26. Schulteis G, Martinez JL Jr: Experience-dependent regulation of Leu-enkephalin hydrolysis in rat plasma. Peptides 14:161–167, 1993
27. Ryan JW, Chung AYK, Nearing JA, Valido FA, Shun-Cun C, Berryer P: A radiochemical assay for aminopeptidase N. Anal Biochem 210:27–33, 1993
28. Lucius R, Sievers J, Mentlein R: Enkephalin metabolism by microglia aminopeptidase-N (CD13). J Neurochem 64:1814–1847, 1995
29. Thornton JR, Losowsky MS: Opioid peptides and primary biliary cirrhosis. BMJ 297:1501–1504, 1988
30. Thornton JR, Dean H, Losowsky MS: Is ascites caused by impaired hepatic inactivation of blood borne endogenous opioid peptides? Gut 29:1167–1172, 1988
31. Thornton JR, Losowsky MS: Methionine enkephalin is increased in plasma in acute liver disease and is present in bile and urine. J Hepatol 8:53–59, 1989
32. Thornton JR, Losowsky MS: Plasma leucine enkephalin is increased in liver diseases. Gut 30:1392–1395, 1989
33. Swain MG, Rothman RB, Xu H, Vergalla J, Bergasa NV, Jones EA: Endogenous opioids accumulate in plasma in rat model of acute cholestasis. Gastroenterology 103:630–635, 1992
34. Yurdaydin C, Li Y, Ha J-H, Jones EA, Rothman R, Basile AS: Brain and plasma levels of opioid peptides are altered in rats with thioacetamide-induced fulminant hepatic failure: Implications for the treatment of hepatic encephalopathy with opioid antagonists. J Pharmacol Exp Ther 273:185–192, 1995
35. Jones EA, Bergasa NV: The pruritus of cholestasis: From bile acids to opiate antagonists. HEPATOLOGY 5:884–887, 1990
36. Bergasa NV, Jones EA: The pruritus of cholestasis: potential pathogenic and therapeutic implications of opioids. Gastroenterology 108:1582–1588, 1995
37. Bergasa NV, Talbot TL, Alling DW, Schmitt JM, Walker EC, Baker BL, Korenman JC, Park Y, Hoofnagle JH, Jones EA: A controlled trial of naloxone infusions for the pruritus of chronic cholestasis. Gastroenterology 102:544–549, 1992
38. Bergasa NV, Alling DW, Talbot TL, Swain MG, Yurdaydin C, Turner ML, Schmidt JM, Walker EC, Jones EA: Effects of naloxone infusions in patients with the pruritus of cholestasis. Ann Intern Med 123:161–167, 1995
39. Janas RM, Trettler J, Warnawin K, Pawlowska J, Rujner J, Socha J: Methionine enkephalin concentration and enkephalin-degrading activity are elevated in blood in children with cholestasis. Eur J Gastroenterol Hepatol 6:539–545, 1994
40. Janas RM, Trettler J, Warnawin K, Pawlowska J, Rujner J, Socha J: Methionine enkephalin and aminopeptidase-M activity in blood in children with cholestasis before and after treatment with ursodeoxycholic acid. In Cholestatic Liver Diseases. GP van Berge Henegouwen, J De Grote, B van Hoek, S Matern, RW Stockbrugger (eds). Dordrecht, Kluwer Academic Publishers, 1994, pp 226–235
41. Janas RM, Marks DL, LaRusso NF: An aluminium silicate binding assay for quantitation of degradation of cholecystokinin octapeptide and other short peptides. Anal Biochem 36:6–11, 1992
42. Xu Y, Wellner D, Schneillberg DA: Substance P and bradykinin are natural inhibitors of CD13/aminopeptidase-N. Biochem Biophys Res Commun 208:664–674, 1995
43. Janas RM: Aminopeptidase-M activity in cholestasis. Is the enzyme a marker or co-factor of the disease? Abstract Book: International Falk Workshop, October 23–24, 1995 Basel, Switzerland, A-40